{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:00:07Z","timestamp":1791453607859,"version":"4.3.3"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10349-x","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T15:56:06Z","timestamp":1739807766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Molecular pathways: the quest for effective MAO-B inhibitors in neurodegenerative therapy"],"prefix":"10.1007","volume":"52","author":[{"given":"Mega Obukohwo","family":"Oyovwi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onoriode Andrew","family":"Udi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adedeji David","family":"Atere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Uchechukwu","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udoji Godsday","family":"Ogbutor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"issue":"8","key":"10349_CR1","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1007\/s12035-023-03328-5","volume":"60","author":"MM Rahman","year":"2023","unstructured":"Rahman MM, Islam MR, Supti FA, Dhar PS, Shohag S, Ferdous J, Shuvo SK, Akter A, Hossain MS, Sharma R (2023) Exploring the therapeutic effect of neurotrophins and neuropeptides in neurodegenerative diseases: at a glance. Mol Neurobiol 60(8):4206\u20134231","journal-title":"Mol Neurobiol"},{"key":"10349_CR2","doi-asserted-by":"crossref","unstructured":"Birajdar SV, Mulchandani M, Mazahir F, Yadav AK. Dementia and neurodegenerative disorder: An introduction. InNanomedicine-based approaches for the treatment of dementia 2023 Jan 1 (pp. 1\u201336). Academic Press.","DOI":"10.1016\/B978-0-12-824331-2.00007-8"},{"key":"10349_CR3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-016-1632-3","volume":"132","author":"DJ Koss","year":"2016","unstructured":"Koss DJ, Jones G, Cranston A, Gardner H, Kanaan NM, Platt B (2016) Soluble pre-fibrillar tau and \u03b2-amyloid species emerge in early human Alzheimer\u2019s disease and track disease progression and cognitive decline. Acta Neuropathol 132:875\u2013895","journal-title":"Acta Neuropathol"},{"issue":"7","key":"10349_CR4","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2174\/1871527320666211006142100","volume":"21","author":"S Kumar","year":"2022","unstructured":"Kumar S, Goyal L, Singh S (2022) Tremor and rigidity in patients with Parkinson\u2019s disease: emphasis on epidemiology, pathophysiology and contributing factors. CNS Neurol Dis-Drug Targets 21(7):596\u2013609","journal-title":"CNS Neurol Dis-Drug Targets"},{"issue":"5","key":"10349_CR5","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/med.21561","volume":"39","author":"RK Tripathi","year":"2019","unstructured":"Tripathi RK, Ayyannan SR (2019) Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: an overview and update. Med Res Rev 39(5):1603\u20131706","journal-title":"Med Res Rev"},{"key":"10349_CR6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00702-014-1362-4","volume":"123","author":"M Naoi","year":"2016","unstructured":"Naoi M, Riederer P, Maruyama W (2016) Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. J Neural Transm 123:91\u2013106","journal-title":"J Neural Transm"},{"issue":"158","key":"10349_CR7","volume":"1","author":"PT Krishnamurthy","year":"2022","unstructured":"Krishnamurthy PT, Kumari M, Byran G, Gangadharappa HV, Garikapati KK (2022) Neuroprotective approaches to halt Parkinson\u2019s disease progression. Neurochem Int 1(158):105380","journal-title":"Neurochem Int"},{"issue":"9","key":"10349_CR8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2174\/1386207323666200402090557","volume":"23","author":"DG Parambi","year":"2020","unstructured":"Parambi DG (2020) Treatment of Parkinson\u2019s disease by MAO-B inhibitors, new therapies and future challenges-A mini-review. Combinatorial Chem High Thr Screening 23(9):847\u201361","journal-title":"Combinatorial Chem High Thr Screening"},{"issue":"69","key":"10349_CR9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pnpbp.2016.02.005","volume":"1","author":"RR Ramsay","year":"2016","unstructured":"Ramsay RR (2016) Molecular aspects of monoamine oxidase B. Prog Neuropsychopharmacol Biol Psychiat 1(69):81\u201389","journal-title":"Prog Neuropsychopharmacol Biol Psychiat"},{"issue":"2","key":"10349_CR10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2014.02.010","volume":"143","author":"JP Finberg","year":"2014","unstructured":"Finberg JP (2014) Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther 143(2):133\u201352","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10349_CR11","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.3390\/molecules26123724","volume":"26","author":"T Behl","year":"2021","unstructured":"Behl T, Kaur D, Sehgal A, Singh S, Sharma N, Zengin G, Andronie-Cioara FL, Toma MM, Bungau S, Bumbu AG (2021) Role of monoamine oxidase activity in Alzheimer\u2019s disease: an insight into the therapeutic potential of inhibitors. Molecules 26(12):3724","journal-title":"Molecules"},{"issue":"2","key":"10349_CR12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1073858420974336","volume":"28","author":"SA Azizi","year":"2022","unstructured":"Azizi SA (2022) Monoamines: dopamine, norepinephrine, and serotonin, beyond modulation, \u201cswitches\u201d that alter the state of target networks. Neuroscientist 28(2):121\u2013143","journal-title":"Neuroscientist"},{"key":"10349_CR13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2147\/JEP.S267032","volume":"29","author":"T M\u00fcller","year":"2021","unstructured":"M\u00fcller T (2021) Experimental dopamine reuptake inhibitors in Parkinson\u2019s disease: a review of the evidence. J Exp Pharmacol 29:397\u2013408","journal-title":"J Exp Pharmacol"},{"issue":"14","key":"10349_CR14","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.3390\/jcm13144130","volume":"13","author":"E Caradonna","year":"2024","unstructured":"Caradonna E, Nemni R, Bifone A, Gandolfo P, Costantino L, Giordano L, Mormone E, Macula A, Cuomo M, Difruscolo R, Vanoli C (2024) The brain-gut axis, an important player in Alzheimer and Parkinson disease: a narrative review. J Clin Med 13(14):4130","journal-title":"J Clin Med"},{"issue":"38","key":"10349_CR15","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.2174\/1381612827666210612051713","volume":"27","author":"MS Rahman","year":"2021","unstructured":"Rahman MS, Uddin MS, Rahman MA, Samsuzzaman M, Behl T, Hafeez A, Perveen A, Barreto GE, Ashraf GM (2021) Exploring the role of monoamine oxidase activity in aging and alzheimer\u2019s disease. Current Pharmaceutical Des 27(38):4017\u201329","journal-title":"Current Pharmaceutical Des"},{"issue":"2","key":"10349_CR16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/antiox11020247","volume":"11","author":"P Duarte","year":"2022","unstructured":"Duarte P, Michalska P, Crisman E, Cuadrado A, Le\u00f3n R (2022) Novel series of dual NRF2 inducers and selective MAO-B inhibitors for the treatment of Parkinson\u2019s disease. Antioxidants 11(2):247","journal-title":"Antioxidants"},{"issue":"174","key":"10349_CR17","volume":"1","author":"C Banerjee","year":"2024","unstructured":"Banerjee C, Barman R, Darshani P, Pillai M, Ahuja S, Mondal R, Pragadheesh VS, Chakraborty J, Kumar D (2024) \u03b1-Viniferin, a dietary phytochemical, inhibits Monoamine oxidase and alleviates Parkinson\u2019s disease associated behavioral deficits in a mice model. Neurochem Int 1(174):105698","journal-title":"Neurochem Int"},{"issue":"19","key":"10349_CR18","doi-asserted-by":"crossref","first-page":"17209","DOI":"10.1074\/jbc.M110920200","volume":"277","author":"RM Geha","year":"2002","unstructured":"Geha RM, Chen K, Wouters J, Ooms F, Shih JC (2002) Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling. J Biol Chem 277(19):17209\u201316","journal-title":"J Biol Chem"},{"issue":"3","key":"10349_CR19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2174\/1389450122666210707120256","volume":"23","author":"A Mannan","year":"2022","unstructured":"Mannan A, Singh TG, Singh V, Garg N, Kaur A, Singh M (2022) Insights into the mechanism of the therapeutic potential of herbal monoamine oxidase inhibitors in neurological diseases. Current Drug Targets 23(3):286\u2013310","journal-title":"Current Drug Targets"},{"issue":"1","key":"10349_CR20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1673-5374.375299","volume":"19","author":"M Alborghetti","year":"2024","unstructured":"Alborghetti M, Bianchini E, De Carolis L, Galli S, Pontieri FE, Rinaldi D (2024) Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings. Neural Regen Res 19(1):16\u201321","journal-title":"Neural Regen Res"},{"key":"10349_CR21","first-page":"26257","volume":"14","author":"DA Flockhart","year":"2012","unstructured":"Flockhart DA (2012) Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. The Primary Care Comp CNS Dis 14:26257","journal-title":"The Primary Care Comp CNS Dis"},{"issue":"7","key":"10349_CR22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-021-00832-x","volume":"35","author":"SR Chamberlain","year":"2021","unstructured":"Chamberlain SR, Baldwin DS (2021) Monoamine oxidase inhibitors (MAOIs) in psychiatric practice: how to use them safely and effectively. CNS Drugs 35(7):703\u2013716","journal-title":"CNS Drugs"},{"issue":"4","key":"10349_CR23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12640-012-9344-5","volume":"23","author":"AF Di Stefano","year":"2013","unstructured":"Di Stefano AF, Radicioni MM, Rusca A (2013) Pressor response to oral tyramine and monoamine oxidase inhibition during treatment with ralfinamide (NW-1029). Neurotox Res 23(4):315\u2013326","journal-title":"Neurotox Res"},{"key":"10349_CR24","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00702-018-1853-9","volume":"125","author":"\u00c9 Sz\u00f6k\u0151","year":"2018","unstructured":"Sz\u00f6k\u0151 \u00c9, T\u00e1bi T, Riederer P, V\u00e9csei L, Magyar K (2018) Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson\u2019s disease. J Neural Transm 125:1735\u20131749","journal-title":"J Neural Transm"},{"key":"10349_CR25","volume":"14","author":"C Banerjee","year":"2024","unstructured":"Banerjee C, Tripathy D, Kumar D, Chakraborty J (2024) Monoamine oxidase and neurodegeneration: mechanisms, inhibitors and natural compounds for therapeutic intervention. Neurochem Int 14:105831","journal-title":"Neurochem Int"},{"key":"10349_CR26","unstructured":"De Beer AD.\u00a0Evaluation of nitrocatechol bearing cyclic chalcones and related analogues as dual monoamine oxidase and catechol-O-methyltransferase inhibitors\u00a0(Doctoral dissertation, North-West University (South-Africa))."},{"issue":"3","key":"10349_CR27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/biomedicines12030549","volume":"12","author":"A Bougea","year":"2024","unstructured":"Bougea A (2024) Some novel therapies in Parkinson\u2019s Disease: a promising path forward or not yet? A systematic review of the literature. Biomedicines 12(3):549","journal-title":"Biomedicines"},{"issue":"6","key":"10349_CR28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40265-019-01098-w","volume":"79","author":"V Cabreira","year":"2019","unstructured":"Cabreira V, Soares-da-Silva P, Massano J (2019) Contemporary options for the management of motor complications in Parkinson\u2019s disease: updated clinical review. Drugs 79(6):593\u2013608","journal-title":"Drugs"},{"issue":"2","key":"10349_CR29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fuctuations: the PRESTO study. Arch Neurol 62(2):241\u2013248","journal-title":"Arch Neurol"},{"issue":"1","key":"10349_CR30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/molecules26010080","volume":"26","author":"B Guieu","year":"2020","unstructured":"Guieu B, Lecoutey C, Legay R, Davis A, de Oliveira S, Santos J, Altomare CD, Catto M, Rochais C, Dallemagne P (2020) First synthesis of racemic trans propargylamino-donepezil, a pleiotrope agent able to both inhibit AChE and MAO-B, with potential interest against Alzheimer\u2019s disease. Molecules 26(1):80","journal-title":"Molecules"},{"issue":"12","key":"10349_CR31","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","volume":"59","author":"A Siderowf","year":"2002","unstructured":"Siderowf A, Stern M, Shoulson I, Kieburtz K, Oakes D, Day D, Shinaman A, Plumb S, Fahn S, Blindauer K, Lew M (2002) A controlled trial of rasagiline in early Parkinson disease: the tempo study. Arch Neurol 59(12):1937\u20131943","journal-title":"Arch Neurol"},{"key":"10349_CR32","unstructured":"Bor\u0161tnar R, Repi\u010d M, Kr\u017ean M, Mavri J, Vianello R. Irreversible inhibition of monoamine oxidase B by the antiparkinsonian medicines rasagiline and selegiline: a computational study."},{"issue":"29","key":"10349_CR33","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.2174\/0929867328666210203204710","volume":"28","author":"Z \u00d6zdemir","year":"2021","unstructured":"\u00d6zdemir Z, Alag\u00f6z MA, Bah\u00e7ecio\u011flu \u00d6F, G\u00f6k S (2021) Monoamine oxidase-B (MAO-B) inhibitors in the treatment of Alzheimer\u2019s and Parkinson\u2019s disease. Curr Med Chem 28(29):6045\u20136065","journal-title":"Curr Med Chem"},{"issue":"9463","key":"10349_CR34","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. The Lancet 365(9463):947\u2013954","journal-title":"The Lancet"},{"issue":"2","key":"10349_CR35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62(2):241\u2013248","journal-title":"Arch Neurol"},{"issue":"30","key":"10349_CR36","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1039\/D4OB00919C","volume":"22","author":"DJ Zou","year":"2024","unstructured":"Zou DJ, Liu RZ, Lv YJ, Guo JN, Fan ML, Zhang CJ, Xie YY (2024) Chromone-deferiprone hybrids as novel MAO-B inhibitors and iron chelators for the treatment of Alzheimer\u2019s disease. Org Biomol Chem 22(30):6189\u20136197","journal-title":"Org Biomol Chem"},{"issue":"29","key":"10349_CR37","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.2174\/0929867328666210203204710","volume":"28","author":"Z \u00d6zdemir","year":"2021","unstructured":"\u00d6zdemir Z, Alag\u00f6z MA, Bah\u00e7ecio\u011flu \u00d6F, G\u00f6k S (2021) Monoamine Oxidase-B (MAO-B) inhibitors in the treatment of Alzheimer\u2019s and Parkinson\u2019s disease. Curr Med Chem 28(29):6045\u20136065","journal-title":"Curr Med Chem"},{"issue":"10","key":"10349_CR38","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3390\/molecules24102005","volume":"24","author":"GD Marconi","year":"2019","unstructured":"Marconi GD, Gallorini M, Carradori S, Guglielmi P, Cataldi A, Zara S (2019) The Up-regulation of oxidative stress as a potential mechanism of novel MAO-B inhibitors for glioblastoma treatment. Molecules 24(10):2005","journal-title":"Molecules"},{"issue":"1","key":"10349_CR39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13041-022-00924-9","volume":"15","author":"SE Park","year":"2022","unstructured":"Park SE, Neupane C, Noh C, Sharma R, Shin HJ, Pham TL, Lee GS, Park KD, Lee CJ, Kang DW, Lee SY, Kim HW, Park JB (2022) Antiallodynic effects of KDS2010, a novel MAO-B inhibitor, via ROS-GABA inhibitory transmission in a paclitaxel-induced tactile hypersensitivity model. Mol Brain 15(1):41","journal-title":"Mol Brain"},{"issue":"1","key":"10349_CR40","doi-asserted-by":"crossref","first-page":"2159957","DOI":"10.1080\/14756366.2022.2159957","volume":"38","author":"Z Cao","year":"2023","unstructured":"Cao Z, Wang X, Zhang T, Fu X, Zhang F, Zhu J (2023) Discovery of novel 2-(4-(benzyloxy)-5-(hydroxyl) phenyl) benzothiazole derivatives as multifunctional MAO-B inhibitors for the treatment of Parkinson\u2019s disease. J Enzyme Inhib Med Chem 38(1):2159957","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"2","key":"10349_CR41","doi-asserted-by":"publisher","first-page":"122","DOI":"10.12997\/jla.2024.13.2.122","volume":"13","author":"J Song","year":"2024","unstructured":"Song J (2024) BDNF signaling in vascular dementia and its effects on cerebrovascular dysfunction, synaptic plasticity, and cholinergic system abnormality. J Lipid Atheroscler 13(2):122\u2013138. https:\/\/doi.org\/10.12997\/jla.2024.13.2.122","journal-title":"J Lipid Atheroscler"},{"issue":"12","key":"10349_CR42","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1096\/fj.05-4910fje","volume":"20","author":"M Yogev-Falach","year":"2006","unstructured":"Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MB (2006) A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J 20(12):2177\u20132179","journal-title":"FASEB J"},{"issue":"6","key":"10349_CR43","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1111\/j.1471-4159.2008.05326.x","volume":"105","author":"E Sanz","year":"2008","unstructured":"Sanz E, Quintana A, Battaglia V, Toninello A, Hidalgo J, Ambrosio S, Valoti M, Marco JL, Tipton KF, Unzeta M (2008) Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells. J Neurochem 105(6):2404\u20132417","journal-title":"J Neurochem"},{"key":"10349_CR44","doi-asserted-by":"publisher","first-page":"1042189","DOI":"10.3389\/fphar.2022","volume":"13","author":"S Rastogi","year":"2022","unstructured":"Rastogi S, Singh A (2022) Gut microbiome and human health: exploring how the probiotic genus Lactobacillus modulate immune responses. Front Pharmacol 13:1042189. https:\/\/doi.org\/10.3389\/fphar.2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10349_CR45","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/nu13010196","volume":"13","author":"BM Gonz\u00e1lez Olmo","year":"2021","unstructured":"Gonz\u00e1lez Olmo BM, Butler MJ, Barrientos RM (2021) Evolution of the human diet and its impact on gut microbiota, immune responses, and brain health. Nutrients 13(1):196","journal-title":"Nutrients"},{"issue":"3","key":"10349_CR46","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/13550280152403254","volume":"7","author":"JR Lokensgard","year":"2001","unstructured":"Lokensgard JR, Hu S, Sheng W, vanOijen M, Cox D, Cheeran MC, Peterson PK (2001) Robust expression of TNF-alpha, IL-1beta, RANTES, and IP-10 by human microglial cells during nonproductive infection with herpes simplex virus. J Neurovirol 7(3):208\u2013219","journal-title":"J Neurovirol"},{"issue":"20","key":"10349_CR47","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.2174\/156802612805220020","volume":"12","author":"J Reis","year":"2012","unstructured":"Reis J, Encarna\u00e7\u00e3o I, Gaspar A, Morales A, Milhazes N, Borges F (2012) Parkinson\u2019s disease management. Part II-discovery of MAO-B inhibitors based on nitrogen heterocycles and analogues. Curr Top Med Chem 12(20):2116\u201330","journal-title":"Curr Top Med Chem"},{"issue":"7","key":"10349_CR48","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/jcm11071931","volume":"11","author":"L Bonanno","year":"2022","unstructured":"Bonanno L, Ciurleo R, Marino S, Ruvolo C, Morabito R, Bramanti A, Corallo F (2022) Effect of MAO-B inhibitors on neurometabolic profile of patients affected by parkinson disease: a proton magnetic resonance spectroscopy study. J Clin Med 11(7):1931","journal-title":"J Clin Med"},{"issue":"2","key":"10349_CR49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/antiox11020247","volume":"11","author":"P Duarte","year":"2022","unstructured":"Duarte P, Michalska P, Crisman E, Cuadrado A, Le\u00f3n R (2022) Novel series of dual NRF2 inducers and selective MAO-B inhibitors for the treatment of Parkinson\u2019s disease. Antioxidants (Basel) 11(2):247","journal-title":"Antioxidants (Basel)"},{"key":"10349_CR50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.676239","volume":"12","author":"M Ostadkarampour","year":"2021","unstructured":"Ostadkarampour M, Putnins EE (2021) Monoamine oxidase inhibitors: a review of their anti-inflammatory therapeutic potential and mechanisms of action. Front Pharmacol 12:676239","journal-title":"Front Pharmacol"},{"issue":"12","key":"10349_CR51","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.3390\/molecules26123724","volume":"26","author":"T Behl","year":"2021","unstructured":"Behl T, Kaur D, Sehgal A, Singh S, Sharma N, Zengin G, Andronie-Cioara FL, Toma MM, Bungau S, Bumbu AG (2021) Role of monoamine oxidase activity in Alzheimer\u2019s disease: an insight into the therapeutic potential of inhibitors. Molecules 26(12):3724","journal-title":"Molecules"},{"issue":"10","key":"10349_CR52","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1023\/A:1016035730754","volume":"13","author":"JS Barrett","year":"1996","unstructured":"Barrett JS, Szego P, Rohatagi S, Morales RJ, De Witt KE, Rajewski G, Ireland J (1996) Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. Pharm Res 13(10):1535\u20131540","journal-title":"Pharm Res"},{"issue":"4","key":"10349_CR53","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/acschemneuro.2c00772","volume":"14","author":"N Nadal-Gratac\u00f3s","year":"2023","unstructured":"Nadal-Gratac\u00f3s N, R\u00edos-Rodr\u00edguez E, Pubill D, Batllori X, Camarasa J, Escubedo E, Berzosa X, L\u00f3pez-Arnau R (2023) Structure-activity relationship of N-Ethyl-Hexedrone analogues: role of the \u03b1-carbon side-chain length in the mechanism of action, cytotoxicity, and behavioral effects in mice. ACS Chem Neurosci 14(4):787\u2013799","journal-title":"ACS Chem Neurosci"},{"key":"10349_CR54","doi-asserted-by":"crossref","first-page":"4216452","DOI":"10.1155\/2022\/4216452","volume":"2022","author":"O Kano","year":"2022","unstructured":"Kano O, Tsuda H, Hayashi A, Arai M (2022) Rasagiline as adjunct to levodopa for treatment of Parkinson\u2019s Disease: A systematic review and meta-analysis. Parkinsons Dis 2022:4216452","journal-title":"Parkinsons Dis"},{"issue":"3","key":"10349_CR55","first-page":"467","volume":"3","author":"S Lecht","year":"2007","unstructured":"Lecht S, Haroutiunian S, Hoffman A, Lazarovici P (2007) Rasagiline\u2014a novel MAO B inhibitor in Parkinson\u2019s disease therapy. Ther Clin Risk Manag 3(3):467\u2013474","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"10349_CR56","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40263-023-01048-x","volume":"37","author":"L Aboulatta","year":"2023","unstructured":"Aboulatta L, Haidar L, Abou-Setta A, Askin N, Rabbani R, Lavu A, Peymani P, Zarychanski R, Eltonsy S (2023) Efficacy and safety of MAO-B inhibitors safinamide and zonisamide in Parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs 37(11):941\u2013956","journal-title":"CNS Drugs"},{"key":"10349_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000541315","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang Z (2024) Effects and safety of monoamine oxidase-B inhibitors for early Parkinson\u2019s disease: a network meta-analysis. Eur Neurol 14:1\u201319","journal-title":"Eur Neurol"},{"issue":"14","key":"10349_CR58","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1517\/14656566.2015.1086748","volume":"16","author":"F Stocchi","year":"2015","unstructured":"Stocchi F, Fossati C, Torti M (2015) Rasagiline for the treatment of Parkinson\u2019s disease: an update. Expert Opin Pharmacother 16(14):2231\u20132241","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10349_CR59","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/jon.12661","volume":"29","author":"JJ Im","year":"2019","unstructured":"Im JJ, Jeong H, Chung YA, Park JS, Heo Y, Oh JK, Song IU (2019) Neuroprotective effects of rasagiline in Parkinson\u2019s disease: a regional cerebral blood flow study. J Neuroimaging 29(6):707\u2013711","journal-title":"J Neuroimaging"},{"issue":"7","key":"10349_CR60","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.3390\/cancers14071812","volume":"14","author":"M Weber","year":"2022","unstructured":"Weber M, Lutz R, Olmos M, Glajzer J, Baran C, Nobis CP, M\u00f6st T, Eckstein M, Kesting M, Ries J (2022) Beyond PD-L1-identification of further potential therapeutic targets in oral cancer. Cancers (Basel) 14(7):1812","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10349_CR61","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00702-023-02623-8","volume":"130","author":"M Regensburger","year":"2023","unstructured":"Regensburger M, Ip CW, Kohl Z, Schrader C, Urban PP, Kassubek J, Jost WH (2023) Clinical benefit of MAO-B and COMT inhibition in Parkinson\u2019s disease: practical considerations. J Neural Transm (Vienna) 130(6):847\u2013861. https:\/\/doi.org\/10.1007\/s00702-023-02623-8","journal-title":"J Neural Transm (Vienna)"},{"issue":"5\u20136","key":"10349_CR62","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00702-022-02465-w","volume":"129","author":"WH Jost","year":"2022","unstructured":"Jost WH (2022) A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease. J Neural Transm (Vienna) 129(5\u20136):723\u2013736","journal-title":"J Neural Transm (Vienna)"},{"issue":"37","key":"10349_CR63","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.2174\/1381612826666200406075044","volume":"26","author":"MS Uddin","year":"2020","unstructured":"Uddin MS, Kabir MT, Rahman MH, Alim MA, Rahman MM, Khatkar A, Al Mamun A, Rauf A, Mathew B, Ashraf GM (2020) Exploring the multifunctional neuroprotective promise of rasagiline derivatives for multi-dysfunctional Alzheimer\u2019s disease. Curr Pharm Des 26(37):4690\u20134698","journal-title":"Curr Pharm Des"},{"issue":"5","key":"10349_CR64","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ana.410430509","volume":"43","author":"NB Mercuri","year":"1998","unstructured":"Mercuri NB, Scarponi M, Federici M, Bonci A, Siniscalchi A, Bernardi G (1998) Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson\u2019s disease. Ann Neurol 43(5):613\u2013617","journal-title":"Ann Neurol"},{"key":"10349_CR65","doi-asserted-by":"crossref","first-page":"1134472","DOI":"10.3389\/fnagi.2023.1134472","volume":"15","author":"K Wang","year":"2023","unstructured":"Wang K, Liu ZH, Li XY, Li YF, Li JR, Hui JJ, Li JX, Zhou JW, Yi ZM (2023) Efficacy and safety of selegiline for the treatment of Parkinson\u2019s disease: a systematic review and meta-analysis. Front Aging Neurosci 15:1134472","journal-title":"Front Aging Neurosci"},{"key":"10349_CR66","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1007\/s00044-019-02423-4","volume":"28","author":"K Wang","year":"2019","unstructured":"Wang K, Yu L, Shi J, Liu W, Sang Z (2019) Multifunctional indanone\u2013chalcone hybrid compounds with anti-\u03b2-amyloid (A \u03b2) aggregation, monoamine oxidase B (MAO-B) inhibition and neuroprotective properties against Alzheimer\u2019s disease. Med Chem Res 28:1912\u20131922","journal-title":"Med Chem Res"},{"issue":"2","key":"10349_CR67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2014.02.010","volume":"143","author":"JP Finberg","year":"2014","unstructured":"Finberg JP (2014) Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther 143(2):133\u2013152","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10349_CR68","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1021\/acs.jmedchem.4c00045","volume":"67","author":"S Giovannuzzi","year":"2024","unstructured":"Giovannuzzi S, Chavarria D, Provensi G, Leri M, Bucciantini M, Carradori S, Bonardi A, Gratteri P, Borges F, Nocentini A, Supuran CT (2024) Dual Inhibitors of brain carbonic anhydrases and monoamine oxidase-b efficiently protect against Amyloid-\u03b2-Induced neuronal toxicity, oxidative stress, and mitochondrial dysfunction. J Med Chem 67(5):4170\u20134193","journal-title":"J Med Chem"},{"issue":"16","key":"10349_CR69","doi-asserted-by":"crossref","first-page":"8359","DOI":"10.1080\/07391102.2023.2265494","volume":"42","author":"MH Mahnashi","year":"2024","unstructured":"Mahnashi MH, Ayaz M, Ghufran M, Almazni IA, Alqahtani O, Alyami BA, Alqahtani YS, Khan HA, Sadiq A, Waqas M (2024) Phytochemicals-based \u03b2-amyloid cleaving enzyme-1 and MAO-B inhibitors for the treatment of Alzheimer\u2019s disease: molecular simulations-based predictions. J Biomol Struct Dyn 42(16):8359\u20138371","journal-title":"J Biomol Struct Dyn"},{"issue":"3","key":"10349_CR70","doi-asserted-by":"crossref","first-page":"eaav0316","DOI":"10.1126\/sciadv.aav0316","volume":"5","author":"JH Park","year":"2019","unstructured":"Park JH, Ju YH, Choi JW, Song HJ, Jang BK, Woo J, Chun H, Kim HJ, Shin SJ, Yarishkin O, Jo S, Park M, Yeon SK, Kim S, Kim J, Nam MH, Londhe AM, Kim J, Cho SJ, Cho S, Lee C, Hwang SY, Kim SW, Oh SJ, Cho J, Pae AN, Lee CJ, Park KD (2019) Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer\u2019s disease. Sci Adv 5(3):eaav0316","journal-title":"Sci Adv"},{"issue":"27","key":"10349_CR71","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202401709","volume":"9","author":"R Rachel Thomas","year":"2024","unstructured":"Rachel Thomas R, Chandran N, Thomas Parambi DG, Kumar S, Alsahli TG, Verma S, Al-Sehemi AG, Mathew B (2024) A comprehensive review of the molecular dynamic study of chalcones, coumarins and chromones as selective MAO-B inhibitors [2015-Till Date]. ChemistrySelect 9(27):e202401709","journal-title":"ChemistrySelect"},{"issue":"10","key":"10349_CR72","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1080\/07391102.2022.2071341","volume":"41","author":"A El Aissouq","year":"2023","unstructured":"El Aissouq A, Chedadi O, Bouachrine M, Ouammou A, Khalil F (2023) Development of novel monoamine oxidase B (MAO-B) inhibitors by combined application of docking-based alignment, 3D-QSAR, ADMET prediction, molecular dynamics simulation, and MM_GBSA binding free energy. J Biomol Struct Dyn 41(10):4667\u20134680","journal-title":"J Biomol Struct Dyn"},{"issue":"3","key":"10349_CR73","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s11030-023-10634-6","volume":"28","author":"GS Baweja","year":"2024","unstructured":"Baweja GS, Gupta S, Kumar B, Patel P, Asati V (2024) Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach. Mol Divers 28(3):1823\u20131845. https:\/\/doi.org\/10.1007\/s11030-023-10634-6","journal-title":"Mol Divers"},{"issue":"8","key":"10349_CR74","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/ene.12724","volume":"22","author":"P Barone","year":"2015","unstructured":"Barone P, Santangelo G, Morgante L, Onofrj M, Meco G, Abbruzzese G, Bonuccelli U, Cossu G, Pezzoli G, Stanzione P, Lopiano L, Antonini A, Tinazzi M (2015) A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson\u2019s disease patients. Eur J Neurol 22(8):1184\u20131191","journal-title":"Eur J Neurol"},{"issue":"3","key":"10349_CR75","volume":"15","author":"M Nemet","year":"2023","unstructured":"Nemet M, Andrijevi\u0107 A, Nedeljkov \u0110, Andri\u0107 V, Gavrilovi\u0107 S (2023) A case report on serotonin syndrome in a patient with Parkinson\u2019s disease: diagnostic and management challenges. Cureus 15(3):e36780","journal-title":"Cureus"},{"issue":"13","key":"10349_CR76","doi-asserted-by":"crossref","first-page":"8905","DOI":"10.1039\/D3RA05501A","volume":"14","author":"S Jalil","year":"2024","unstructured":"Jalil S, Hussain Z, Abid SMA, Hameed A, Iqbal J (2024) Quinoline-sulfonamides as a multi-targeting neurotherapeutic for cognitive decline: in vitro, in silico studies and ADME evaluation of monoamine oxidases and cholinesterases inhibitors. RSC Adv 14(13):8905\u20138920","journal-title":"RSC Adv"},{"issue":"2","key":"10349_CR77","doi-asserted-by":"crossref","first-page":"588","DOI":"10.31788\/RJC.2023.1628184","volume":"16","author":"NL Saadah","year":"2023","unstructured":"Saadah NL, Darmawan MF, Dewantari MB, Haq KU, Suwito H (2023) Exploration of pyrazoline and amino chalcone derivatives as monoamine oxidase inhibitors: an in-silico approach. Rasayan J Chem 16(2):588\u201395","journal-title":"Rasayan J Chem"},{"issue":"10","key":"10349_CR78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.14295\/bjs.v3i10.634","volume":"3","author":"L Figueroa-Valverde","year":"2024","unstructured":"Figueroa-Valverde L, Rosas-Nexticapa M, Alvarez-Ramirez M, Aguilar-Sanchez E, Mateu-Armad MV (2024) Interaction of dihydrofuran-2-one and its derivatives with either MAO-B or COMT enzymes using a theoretical model. Brazilian J Sci 3(10):28\u201344","journal-title":"Brazilian J Sci"},{"issue":"7","key":"10349_CR79","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.21873\/anticanres.15858","volume":"42","author":"Y Saito","year":"2022","unstructured":"Saito Y, Takekuma Y, Takeshita T, Noguchi T, Takeuchi S, Shimizu Y, Kinoshita I, Dosaka-Akita H, Sugawara M (2022) Risk factor analysis for the occurrence of severe adverse effects in eribulin treatment. Anticancer Res 42(7):3693\u20133700","journal-title":"Anticancer Res"},{"key":"10349_CR80","first-page":"S8","volume":"6","author":"YB Hu","year":"2017","unstructured":"Hu YB, Zhang Q, Li HJ, Michot JM, Liu HB, Zhan P, Lv TF, Song Y (2017) written on behalf of the AME Academic lung cancer cooperation group. evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res 6:S8\u2013S20","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"10349_CR81","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1055\/s-2007-1017119","volume":"20","author":"A Steiger","year":"1987","unstructured":"Steiger A, Holsboer F, Gerken A, Demisch L, Benkert O (1987) Results of an open clinical trial of brofaromine (CGP 11 305 A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depression. Pharmacopsychiatry 20(6):262\u2013269","journal-title":"Pharmacopsychiatry"},{"key":"10349_CR82","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s007020050209","volume":"106","author":"A Fredriksson","year":"1999","unstructured":"Fredriksson A, Palomo T, Archer T (1999) Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub-\/suprathreshold doses of L-Dopa upon motor behaviour of MPTP-treated mice. J Neural Transm 106:889\u2013909","journal-title":"J Neural Transm"},{"issue":"6","key":"10349_CR83","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00002826-200011000-00005","volume":"23","author":"JM Rabey","year":"2000","unstructured":"Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G, Rasagiline Study Group (2000) Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson\u2019s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23(6):324\u201330","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10349_CR84","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/1570180820666230427092537","volume":"21","author":"BC Phukan","year":"2024","unstructured":"Phukan BC, Roy R, Choudhury S, Bhattacharya P, Borah A (2024) Neuroprotective potential of polydatin in combating Parkinson\u2019s disease through the inhibition of monoamine oxidase-b and catechol-o-methyl transferase. Lett Drug Des Dis 21(1):180\u2013188","journal-title":"Lett Drug Des Dis"},{"issue":"44","key":"10349_CR85","volume":"100","author":"Y Wang","year":"2021","unstructured":"Wang Y, Jiang DQ, Lu CS, Li MX, Jiang LL (2021) Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: a systematic review and meta-analysis. Medicine (Baltimore) 100(44):e27511","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10349_CR86","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000527060","volume":"52","author":"KL Sloane","year":"2023","unstructured":"Sloane KL, Fabian R, Wright A, Saxena S, Kim K, Stein CM, Keser Z, Glenn S, Hillis AE (2023) Supervised, self-administered tablet-based cognitive assessment in neurodegenerative disorders and stroke. Dement Geriatr Cogn Disord 52(2):74\u201382","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"10349_CR87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282428","volume":"18","author":"SK Highlander","year":"2023","unstructured":"Highlander SK, Wood JM, Gillece JD, Folkerts M, Fofanov V, Furstenau T, Singh NK, Guan L, Seuylemezian A, Benardini JN, Engelthaler DM, Venkateswaran K, Keim PS (2023) Multi-faceted metagenomic analysis of spacecraft associated surfaces reveal planetary protection relevant microbial composition. PLoS ONE 18(3):e0282428","journal-title":"PLoS ONE"},{"issue":"2","key":"10349_CR88","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00210-023-02637-9","volume":"397","author":"MO Oyovwi","year":"2024","unstructured":"Oyovwi MO, Ben-Azu B, Falajiki FY, Onome OB, Rotu RA, Rotu RA, Oyeleke AA, Okwute GP, Moke EG (2024) D-ribose-L-cysteine exhibits restorative neurobehavioral functions through modulation of neurochemical activities and inhibition oxido-inflammatory perturbations in rats exposed to polychlorinated biphenyl. Naunyn Schmiedebergs Arch Pharmacol 397(2):931\u2013945","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10349_CR89","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112022","volume":"142","author":"MO Oyovwi","year":"2021","unstructured":"Oyovwi MO, Ben-Azu B, Edesiri TP, Victor E, Rotu RA, Ozegbe QE, Nwangwa EK, Atuadu V, Adebayo OG (2021) Kolaviron abates busulfan-induced episodic memory deficit and testicular dysfunction in rats: the implications for neuroendopathobiological changes during chemotherapy. Biomed Pharmacother 142:112022","journal-title":"Biomed Pharmacother"},{"issue":"13","key":"10349_CR90","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/bph.13318","volume":"173","author":"O Weinreb","year":"2016","unstructured":"Weinreb O, Amit T, Bar-Am O, Youdim MB (2016) Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and \u03b2-amyloid in ageing and Alzheimer\u2019s disease. Br J Pharmacol 173(13):2080\u20132094","journal-title":"Br J Pharmacol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10349-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10349-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10349-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:24:54Z","timestamp":1766852694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10349-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10349"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10349-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors. Informed consent was obtained from all authors included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"240"}}